What is Acomplia?
What is Acomplia?
* Acomplia is the first in a new class of healing(p) agents named Cannabinoid-1 Receptor Blockers.
* Acomplia is used in the treatment of obesity and related conditions.
How does Acomplia work?
* Acomplia acts by selectively blocking CB1 receptors found in the judgment and in computer peripheral organs of import in glucose and lipid metabolism, including adipose tissue, the liver, gi tract and muscle.
* Acomplia switches off the same brain circuits that make people hungry when they smoke hempen necktie.
* CB1 receptor hinder with Acomplia acts to step-down the overactivity of the endocannabinoid connive. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid metabolism.
What is Acomplia used for?
* Acomplia is used completing to diet and exercise to treat weighty or overweight patients who hurt? from Type 2 diabetes and abnormal levels of fat in the blood.
* Sanofi argues that Acomplia can also foreclose the risk of cardiovascular disease.
* Patients with large shank circumference will in general realise from using the drug.
Does Acomplia also aid smoking cessation?
* Acomplia has been deliberate by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
* Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation. An approvable letter was however issued for Acomplia for use in weight direction.
Acomplia has just been approved in the European Union. Is Acomplia approved in the United States?
* No. Sanofi is still awaiting U.S. marketing green light which it has said could come by the end of this year.
* U.S. health authorities have asked Sanofi for more information on Acomplia.
* Acomplia received European Union marketing approving in June 2006.
* The first plunge will use place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi.
What were the results of Acomplia Clinical visitation studies?
* In clinical studies, Acomplia has been shown to best a wide array of cardiometabolic risk factors as well as promoting free burning weight loss.
* or so half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C in patients who received Acomplia 20mg was on the far side that likely from weight loss alone(p).
